Диссертация (1173577), страница 49
Текст из файла (страница 49)
Special patent provisions for pharmaceuticals: Have thayoutlived their usefulness?, IDEA, 1999. P. 39.26.Fellmeth A.X. Secrecy, Monopoly, and Access to Pharmaceuticals inInternational Trade Law (2004) 45 Harv. Int'l L.J. P. 443, 446.27.Frank R.G. Editorial: New estimates of drug development costs. J HealthEcon. 2003;22: 325-30. PunMedCrossRef.28.2002.FTC. Generic drug entry prior to patent expiration: An FTC study, JulyURL:https://www.ftc.gov/sites/default/files/documents/reports/generic-drug-entry-prior-patent-expiration-ftc-study/genericdrugstudy_0.pdf(датаобращения:30.04.2017).29.century.Galvez-Behar G. Was the French Patent System democratic? France, 19th2008.URL:https://halshs.archives-ouvertes.fr/halshs-00544730/PDF/FPS_V3.pdf (дата обращения: 30.04.2017).30.Gervais B.L.
Life Sciences and Chemical Patent Practice in Canada:A Practical Guide. Borden Ladner Gervais LLP, 2011. P. 93.23431.Gervais D. The TRIPS agreement. Drafting history and analysis (Thomson-Sweet and Maxwell, 2nd edition, 2006).32.Grabowski H. Data exclusivity for biologics: What is the appropriate priodof protection? AEI Outlook Series, 2009. URL: www.aei.org/outlook/100068 (датаобращения: 30.04.2017).33.Hamdouch А., Perrochon D.
Formes d'engagement en R&D, processusd'innovation et modalités d'interaction entre firmes dans l'industrie pharmaceutique,Revue d'économie industrielle, – 2000, Volume 93, Numéro 1. P. 29 – 5034.Hartridge D., Subramanian A. “Intellectual Property Rights: The Issues inGATT” 22 Vanderbilt Journal of Transnational Law.35.Hathaway C., Manthei J. and Scherer C. Exclusivity Strategies in theUnited States and European Union May/June 2009 Issue 3 With Permission from FDLI.URL: http://www.lw.com/upload/pubcontent/_pdf/pub2655_1.pdf (дата обращения:30.04.2017).36.Holman C.M. “Do Reverse Payment Settlements Violate the AntitrustLaws?”, (2007).
Vol. 23.37.International Jurisdiction in Intellectual Property Disputes: CLIP, ALIPrinciples and other Legislative Proposals in a Comparative Perspective, Paulius Jurcys,JIPITEC,Vol.3,No.3(2012).P. 174-226.http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2160076(датаURL:обращения:13.09.2016).38.Junod V. Drug Marketing Exclusivity under United States and EuropeanUnion Law, 59 FOOD & DRUG L.J., – 2004. P. 479.39.Kingham and Castle (2000), “Data and marketing exclusivity forpharmaceuticals in the European Community”, Food & Drug L.J.
P. 55.40.Korn D.E., Lietzan E. and Scott S.W. (2009) A new history and discussionof 180-day exclusivity, Food & Drug L.J. P. 64.41.Krattiger A., Mahoney R.T., Nelsen L. (eds), Intellectual PropertyManagement in Health and Agricultural Innovation: A Handbook of Best Practices(MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A, – 2007. P. 440.23542.Kucukarslan S.
and Cole J. Patent extension under the drug pricecompetition and Patent Term Restoration Act of 1984, Food & Drug L.J. – 1994. P.511.43.Ladas S.P. Patents, Trademarks, and Related Rights: National andInternational Protection, Cambridge, Massachusetts: Harvard University Press, 1975. P.283.44.Landes W.M. and Posner R.A. The economic structure of Intellectualproperty Law. (Harvard University Press 2003) – P. 354 – 355.45.Lando O. Contracts / International Encyclopedia of Comparative Law. P.46.Leaffer M.A. International Treaties on Intellectual Property, 2d ed.,141.Washington: The Bureau of National Affairs, Inc., 1997. P.17.47.Lisman and Schoonderbeck And introduction to EU Pharmaceutical Law,Brookwood Medical Publications, Brookwook, – 2005.
P. 71.48.Lutz D. Purpose- or function-related product protection, with particularregard to biotechnological inventions, OJ EPO, Special Edition 2, – 2007. P. 170.49.Lybecker K.M., Fowler E. Compulsory Licensing in Canada and Thailand:Comparing Regimes to Ensure Legitimate Use of the WTO Rules Journal of Law,Medicine & Ethics 37, – 2009.
P. 222 – 239.50.Machlup F., Penrose E.T. The Patent Controversy in the NineteenthCentury, The Journal Economic History , Vol. 10, No. 1 (May, 1950). P. 1– 29. URL:http://c4sif.org/wp-content/uploads/2010/09/Machlup-Penrose-The-Patent-Controversyin-the-Nineteenth-Century-1950-b.pdf (дата обращения: 30.04.2017).51.Mathur V., Dr. Nagori B.P., Dr. Tiwari M.
Compulsory Licensing ofPharmaceutical Patents in India: A Research Study, European Journal of PharmaceuticalandMedicalResearch,2016,3(3),532-543,EJPMR.URL:http://www.ejpmr.com/admin/assets/article_issue/1457001699.pdf (дата обращения:30.04.2017).52.DefensiveMavroghenis S. Article 82 EC and Strategic Patenting – Patent Thickets,Patents,andFollow-onPatents.P. 4.URL:236http://www.droit.ulg.ac.be/ieje/fileadmin/IEJE/Pdf/Mavroghenis_Strategic_Patenting_and_Article_82_EC.p (дата обращения: 30.04.2017).53.Merges R.
Patent law and policy. Cases and materials, Contemporary LegalEducational Series, Boston, 1992.54.Moufang R. Use and purpose indications in patent claims, OJ EPO, Specialedition, 2011. P. 116.Myers S. B. A Healthy Solution for Patients and Patents: How India’s55.Legal Victory Against A Pharmaceutical Giant Reconciles Human Rights withIntellectual Property Rights, 2008, 10 Vanderbilt Journal of Entertainment andTechnology Law.
P. 763.Nogués J. J. Patents and Pharmaceutical Drugs: Understanding the Pressure56.on Developing Countries (1990) 24(6) – Journal of World Trade.Nogués J.J. Social Costs and Benefits of Introducing Patent Protection for57.Pharmaceutical Drugs in Developing Countries (1993) XXXI(1) The DevelopmentEconomies P. 24.Oliveira M.
A., Bermudez J.A.Z., Chaves G.C., Velásquez G. Has the58.implementation of the TRIPS Agreement in Latin America and the Caribbean producedintellectualpropertylegislationthatfavourspublichealth?// URL:http://www.who.int/bulletin/volumes/82/11/en/815.pdf (дата обращения: 30.04.2017).59.Patel S. J.
The Patent System and the Third World, 1974, 2 (9) WorldDevelopment 3 table 2 at 6.60.Penrose E.T. The Economics of the International Patent System (Baltimore:Johns Hopkins Press, 1951) at 19–40.61.Prinz zu Waldeck W. und Pyrmont Special legislation for geneticinventions – Aviolation of Article 27(1) TRIPS?, In Patent and Technological Progressin a Globalized World, Liber Amicorum Joseph Straus, Berlin/Heidelberg, 2009. P.
289.62.Qualification Process for Drug Development Tools, U.S. Department ofHealth and Human Services Food and Drug Administration Center for Drug EvaluationandResearch(CDER)January2014,Procedural.URL:237http://www.fda.gov/forpatients/approvals/drugs/default.htm(датаобращения:30.04.2017).63.Raines L. (1999). Biotechnology and patent term extension issues.
Food &Drug L.J. P.23964.Reichman J.H. Rethinking the Role of Clinical Trial Data in InternationalIntellectual Property Law: The Case for a Public Goods Approach (2009). 13 MarquetteIntellectual Property Law Review. P. 1-68.65.Roane K.R. (2011). «Generics» new legal attack: Big pharma’s agingpatents’, Fortune.66.Roffe P. Abuses of Patent Monopoly: A Legal Appraisal (1974) 2(9) WorldDevelopment 15.67.Rothman S.S. Lessons from the living cell: the culture of science and thelimits of reductionism.
— New York: McGraw-Hill, 2002. — ISBN 0-07-137820-0.68.Rzakhanov, Z. (2008). Regulatory policy, value of khowledge assts andinnovation strategy: The case of the Orphan Drug Act. Research Policy, 37. P. 688.69.San Juan J. R. U.S and E.U Protection of Pharmaceutical Test Data. 1(2006)CPTechDiscussionPaperDiscussionhttp://www.cptech.org/publications/CPTechDPNo1TestData.pdf(датаPaper // URL:обращения:30.04.2017).70.Satyanarayana K., Srivastava S. and Ganguly NK. 2006. Data ProtectionIssues in India. Indian Journal of Medical Research. P.123.71.Sell S. K. Intellectual Property as a Trade Issue: From the Paris Conventionto GATT (1989).
XIII, Legal Studies Forum. P. 407–422.72.Schellekens H. Jiskoot W. Letter to the editor, eprex-associated pure redcell aplasia and leachtes. 24 Nature Biotechnol. 2006. P. 613–614.73.Schuster M. The Court of Justice of the European Union’s Ruling on thePatentability of Human Embryonic Stem-Cell-Related Inventions, – 2012, IIC.
P. 43.74.Shanker D. Developing Countries, China and Economic Institutions (2001)paper presented at the Thirteenth Annual Association for Chinese Economic StudiesInternational Conference (China’s Economy: Confronting Restructuring Stability and238InternationalCompetitiveness),July14-15,2001attheUniversityofWollongong, Australia. URL: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=277928 (дата обращения: 30.04.2017).75.Singer N. In pursuit of a pipeline of biological treatments. – New York:New York Times; January 27, 2009.76.Sykes A.O.
TRIPS, Pharmaceuticals, Developing Countries, and the Doha‘Solution (2002) 3(1) // Chicago Journal of International Law. P. 47.77.T’H. E. TRIPS, pharmaceutical patents, and access to essential medicines:a long way from Seattle to Doha // Chicago Journal International of Law, – 2002.P. 27 –48.78.Terrell T. and Shelley C. The Law of Patents 248 (1952). P. 467.79.Thamoas, J.R. (2010).
The value of patent term extensions to thepharmaceutical industry in the USA // Journal of Generic Medicines, 5, p. 201.80.Thamoas, J.R. (2010). Pharmaceutical Patent Law, 2nd edition, BNABooks Arlington.81.The Protection of Undisclosed Test Data in Accordance with TRIPSArticle 39.3, Office of the General Counsel of USTR for submission in bilateraldiscussions with Australia, May 1995.82.Trioni P.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
